Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

Dec 7 2010

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the International Respiratory Syncytial Virus Symposium, which took place in Rotterdam, Netherlands on December 2-5, 2010. The presentation was given by Barney S. Graham, MD, PhD, Chief, Viral Pathogenesis Laboratory and Chief, Clinical Trials Core, at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH). In his plenary address, Dr. Graham highlighted work VRC and GenVec are conducting under a Cooperative Research and Development Agreement (CRADA).

Data presented at the conference demonstrated encouraging preclinical proof-of-concept findings generated in multiple animal models at the NIH and GenVec.  Specifically, the data show sustained production of neutralizing antibodies and the lack of immunological responses associated with adverse events linked to prior unsuccessful RSV vaccine approaches.

"These data are promising and show that a vaccine utilizing our technology has significant potential to prevent RSV," stated Jason Gall, PhD, a Senior Director of Research at GenVec and the company's lead RSV scientist. "Currently, there is no approved RSV vaccine and we are excited to be moving toward filling the need for a safe and effective RSV vaccine."